MX390964B - Formas cristalinas de un inhibidor tipo lisil oxidasa 2 y metodos de realizacion. - Google Patents
Formas cristalinas de un inhibidor tipo lisil oxidasa 2 y metodos de realizacion.Info
- Publication number
- MX390964B MX390964B MX2019002615A MX2019002615A MX390964B MX 390964 B MX390964 B MX 390964B MX 2019002615 A MX2019002615 A MX 2019002615A MX 2019002615 A MX2019002615 A MX 2019002615A MX 390964 B MX390964 B MX 390964B
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- crystalline forms
- loxl2
- inhibitor
- lysyl oxidase
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 5
- 101001043322 Mus musculus Lysyl oxidase homolog 1 Proteins 0.000 title 1
- 101001043352 Homo sapiens Lysyl oxidase homolog 2 Proteins 0.000 abstract 6
- 102100021948 Lysyl oxidase homolog 2 Human genes 0.000 abstract 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- ODGXXYXJORZPHE-ZIAGYGMSSA-N [3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxyphenyl]-[(3R,4R)-3-fluoro-4-hydroxypyrrolidin-1-yl]methanone Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C=CC=1)C(=O)N1C[C@H]([C@@H](C1)O)F ODGXXYXJORZPHE-ZIAGYGMSSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/63—Esters of sulfonic acids
- C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
- C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
- C07C309/66—Methanesulfonates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Catalysts (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662384596P | 2016-09-07 | 2016-09-07 | |
| PCT/US2017/050332 WO2018048943A1 (en) | 2016-09-07 | 2017-09-06 | Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019002615A MX2019002615A (es) | 2019-10-15 |
| MX390964B true MX390964B (es) | 2025-03-21 |
Family
ID=61561660
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019002615A MX390964B (es) | 2016-09-07 | 2017-09-06 | Formas cristalinas de un inhibidor tipo lisil oxidasa 2 y metodos de realizacion. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10774069B2 (enExample) |
| EP (1) | EP3510023B1 (enExample) |
| JP (1) | JP7079772B2 (enExample) |
| KR (1) | KR102587178B1 (enExample) |
| CN (1) | CN109983006B (enExample) |
| AU (1) | AU2017324445A1 (enExample) |
| BR (1) | BR112019004517A2 (enExample) |
| CA (1) | CA3036064A1 (enExample) |
| EA (1) | EA201990621A1 (enExample) |
| IL (1) | IL265192A (enExample) |
| MA (1) | MA46204A (enExample) |
| MX (1) | MX390964B (enExample) |
| SG (1) | SG11201901999XA (enExample) |
| WO (1) | WO2018048943A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3795568A1 (en) | 2015-03-06 | 2021-03-24 | Pharmakea, Inc. | Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof |
| JP6800872B2 (ja) * | 2015-03-06 | 2020-12-16 | ファーマケア，インク． | リシルオキシダーゼ様２阻害剤とその使用 |
| CA3013917A1 (en) | 2016-02-09 | 2017-08-17 | Pharmakea, Inc. | Quinolinone lysyl oxidase-like 2 inhibitors and uses thereof |
| JP7097874B2 (ja) | 2016-09-07 | 2022-07-08 | ファーマケア，インク． | リシルオキシダーゼ様２阻害剤の使用 |
| AU2017324445A1 (en) | 2016-09-07 | 2019-04-11 | Pharmakea, Inc. | Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making |
| GB201716871D0 (en) | 2017-10-13 | 2017-11-29 | Inst Of Cancer Research: Royal Cancer Hospital | Compounds |
| CN114487139B (zh) * | 2020-10-27 | 2025-01-14 | 鲁南制药集团股份有限公司 | 一种盐酸西替利嗪有关物质的检测方法 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4229447A (en) | 1979-06-04 | 1980-10-21 | American Home Products Corporation | Intraoral methods of using benzodiazepines |
| IE56702B1 (en) | 1982-12-01 | 1991-11-06 | Usv Pharma Corp | Antiinflammatory antiallergic compounds |
| US4596795A (en) | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
| US4755386A (en) | 1986-01-22 | 1988-07-05 | Schering Corporation | Buccal formulation |
| US5021456A (en) | 1988-02-25 | 1991-06-04 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
| US5739136A (en) | 1989-10-17 | 1998-04-14 | Ellinwood, Jr.; Everett H. | Intraoral dosing method of administering medicaments |
| US5563143A (en) | 1994-09-21 | 1996-10-08 | Pfizer Inc. | Catechol diether compounds as inhibitors of TNF release |
| US6956047B1 (en) | 1995-06-06 | 2005-10-18 | Pfizer Inc. | Corticotropin releasing factor antagonists |
| US7067664B1 (en) | 1995-06-06 | 2006-06-27 | Pfizer Inc. | Corticotropin releasing factor antagonists |
| US6632823B1 (en) | 1997-12-22 | 2003-10-14 | Merck & Co., Inc. | Substituted pyridine compounds useful as modulators of acetylcholine receptors |
| HRP20020599A2 (en) | 2000-01-18 | 2004-08-31 | Pfizer Prod Inc | Corticotropin releasing factor antagonists |
| US7105682B2 (en) | 2001-01-12 | 2006-09-12 | Amgen Inc. | Substituted amine derivatives and methods of use |
| US6878714B2 (en) | 2001-01-12 | 2005-04-12 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| US7102009B2 (en) | 2001-01-12 | 2006-09-05 | Amgen Inc. | Substituted amine derivatives and methods of use |
| US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| US20030134836A1 (en) | 2001-01-12 | 2003-07-17 | Amgen Inc. | Substituted arylamine derivatives and methods of use |
| US20020147198A1 (en) | 2001-01-12 | 2002-10-10 | Guoqing Chen | Substituted arylamine derivatives and methods of use |
| US7307088B2 (en) | 2002-07-09 | 2007-12-11 | Amgen Inc. | Substituted anthranilic amide derivatives and methods of use |
| FI20030030A0 (fi) | 2003-01-09 | 2003-01-09 | Orion Corp | Uusia yhdisteitä |
| ATE537825T1 (de) | 2003-05-19 | 2012-01-15 | Irm Llc | Immunosuppressive verbindungen und zusammensetzungen |
| BRPI0507250A (pt) | 2004-01-29 | 2007-06-26 | Pfizer Prod Inc | combinações para tratar desordens do snc |
| US7381750B2 (en) | 2004-03-12 | 2008-06-03 | Eli Lilly And Company | Amino-phenoxymethyl-benzamide opioid receptor antagonists |
| ATE545413T1 (de) | 2004-03-15 | 2012-03-15 | Lilly Co Eli | Antagonisten des opioidrezeptors |
| CA2564085C (en) | 2004-04-30 | 2013-04-02 | Takeda Pharmaceutical Company Limited | Heterocyclic amide compound and use thereof as an mmp-13 inhibitor |
| US7507748B2 (en) | 2004-07-22 | 2009-03-24 | Amgen Inc. | Substituted aryl-amine derivatives and methods of use |
| WO2006027691A2 (en) | 2004-09-10 | 2006-03-16 | Pfizer Products Inc. | Methods of treating mood disorders using benzisoxazole containing diazabicyclic compounds |
| MX2007002842A (es) | 2004-09-10 | 2007-04-30 | Pfizer Prod Inc | Metodos de tratamiento de trastornos cognitivos que usan derivados azabiciclicos de piridiloximetilo y benzoisoxazol. |
| WO2006052546A2 (en) | 2004-11-04 | 2006-05-18 | Neurogen Corporation | Pyrazolylmethyl heteroaryl derivatives |
| DE102004056226A1 (de) | 2004-11-22 | 2006-05-24 | Burchardt, Elmar Reinhold, Dr.Dr. | Neuartige Inhibitoren der Lysyloxidase |
| AU2006210954A1 (en) | 2005-01-31 | 2006-08-10 | Merck & Co., Inc. | Antidiabetic bicyclic compounds |
| AR055041A1 (es) | 2005-03-23 | 2007-08-01 | Merck Frosst Canada Ltd | Tiadiazoles y oxadiazoles como inhibidores de la sintesis de leucotrienos. composiciones farmaceuticas. |
| AU2006279211A1 (en) | 2005-08-11 | 2007-02-15 | Merck Frosst Canada Ltd | Novel substituted 1,2,3-triazolylmethyl-benzothiophene or -indole and their use as leukotriene biosynthesis inhibitors |
| US7405302B2 (en) | 2005-10-11 | 2008-07-29 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (FLAP) inhibitors |
| ITMI20051943A1 (it) * | 2005-10-14 | 2007-04-15 | Procos Spa | Processo di risoluzione anantiomerica di 2-aminometil-pirrolidine 1-sostitute per ammidazione in presenza di lipasi |
| US20070225285A1 (en) | 2005-11-04 | 2007-09-27 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
| US7977359B2 (en) | 2005-11-04 | 2011-07-12 | Amira Pharmaceuticals, Inc. | 5-lipdxygenase-activating protein (FLAP) inhibitors |
| US20070219206A1 (en) | 2005-11-04 | 2007-09-20 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
| CA2636043A1 (en) | 2006-01-23 | 2007-08-02 | Amira Pharmaceuticals, Inc. | Tricyclic inhibitors of 5-lipoxygenase |
| GB0614579D0 (en) | 2006-07-21 | 2006-08-30 | Black James Foundation | Pyrimidine derivatives |
| WO2008020799A1 (en) | 2006-08-18 | 2008-02-21 | Astrazeneca Ab | Thienopyrimidin-4-one and thienopyridazin-7-one derivatives as mch rl antagonists |
| IL184627A0 (en) | 2007-07-15 | 2008-12-29 | Technion Res & Dev Foundation | Agents for diagnosing and modulating metastasis and fibrosis as well as inflammation in a mammalian tissue |
| CN110372795A (zh) | 2007-08-02 | 2019-10-25 | 吉利德生物制剂公司 | Lox和loxl2抑制剂及其应用 |
| JP2013500974A (ja) | 2009-07-28 | 2013-01-10 | アナコール ファーマシューティカルズ，インコーポレイテッド | 三置換ホウ素含有分子 |
| AU2010284001A1 (en) | 2009-08-21 | 2012-03-22 | Gilead Biologics, Inc. | Therapeutic methods and compositions |
| RU2015108348A (ru) | 2010-02-04 | 2015-07-20 | Джилид Байолоджикс, Инк. | Антитела, связывающиеся с лизилоксидазоподобным ферментом-2 (loxl2), и способы их применения |
| CN103002742B (zh) | 2010-03-05 | 2016-07-13 | 卡尔约药物治疗公司 | 核转运调节剂及其应用 |
| CN103415515B (zh) | 2010-11-19 | 2015-08-26 | 因塞特公司 | 作为jak抑制剂的环丁基取代的吡咯并吡啶和吡咯并嘧啶衍生物 |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物 |
| WO2013059587A1 (en) | 2011-10-20 | 2013-04-25 | Sirtris Pharmaceuticals, Inc. | Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators |
| US9701658B2 (en) | 2012-04-25 | 2017-07-11 | Raqualia Pharma Inc. | Amide derivatives as TTX-S blockers |
| SG11201503065PA (en) | 2012-10-30 | 2015-05-28 | Gilead Sciences Inc | Therapeutic and diagnostic methods related to lysyl oxidase-like 2 (loxl2) |
| WO2014098098A1 (ja) | 2012-12-18 | 2014-06-26 | 味の素株式会社 | 複素環アミド誘導体及びそれを含有する医薬 |
| CA2939655A1 (en) | 2014-02-14 | 2016-02-11 | The University Of British Columbia | Modulators of caspase-6 |
| US9051320B1 (en) | 2014-08-18 | 2015-06-09 | Pharmakea, Inc. | Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor |
| CN107922392B (zh) | 2015-02-15 | 2020-07-21 | 豪夫迈·罗氏有限公司 | 1-(杂)芳基磺酰基-(吡咯烷或哌啶)-2-甲酰胺衍生物及其用途 |
| JP6800872B2 (ja) | 2015-03-06 | 2020-12-16 | ファーマケア，インク． | リシルオキシダーゼ様２阻害剤とその使用 |
| EP3795568A1 (en) * | 2015-03-06 | 2021-03-24 | Pharmakea, Inc. | Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof |
| JP7097874B2 (ja) | 2016-09-07 | 2022-07-08 | ファーマケア，インク． | リシルオキシダーゼ様２阻害剤の使用 |
| AU2017324445A1 (en) * | 2016-09-07 | 2019-04-11 | Pharmakea, Inc. | Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making |
-
2017
- 2017-09-06 AU AU2017324445A patent/AU2017324445A1/en not_active Abandoned
- 2017-09-06 EA EA201990621A patent/EA201990621A1/ru unknown
- 2017-09-06 CA CA3036064A patent/CA3036064A1/en active Pending
- 2017-09-06 SG SG11201901999XA patent/SG11201901999XA/en unknown
- 2017-09-06 JP JP2019512640A patent/JP7079772B2/ja active Active
- 2017-09-06 US US16/331,095 patent/US10774069B2/en active Active
- 2017-09-06 MX MX2019002615A patent/MX390964B/es unknown
- 2017-09-06 WO PCT/US2017/050332 patent/WO2018048943A1/en not_active Ceased
- 2017-09-06 BR BR112019004517-1A patent/BR112019004517A2/pt not_active IP Right Cessation
- 2017-09-06 CN CN201780068733.0A patent/CN109983006B/zh active Active
- 2017-09-06 MA MA046204A patent/MA46204A/fr unknown
- 2017-09-06 KR KR1020197009870A patent/KR102587178B1/ko active Active
- 2017-09-06 EP EP17849479.5A patent/EP3510023B1/en active Active
-
2019
- 2019-03-06 IL IL265192A patent/IL265192A/en unknown
-
2020
- 2020-08-03 US US16/983,759 patent/US11459309B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| IL265192A (en) | 2019-05-30 |
| CN109983006A (zh) | 2019-07-05 |
| JP7079772B2 (ja) | 2022-06-02 |
| EP3510023A4 (en) | 2020-03-18 |
| SG11201901999XA (en) | 2019-04-29 |
| CN109983006B (zh) | 2022-02-25 |
| EA201990621A1 (ru) | 2019-09-30 |
| WO2018048943A1 (en) | 2018-03-15 |
| AU2017324445A1 (en) | 2019-04-11 |
| MA46204A (fr) | 2021-03-17 |
| JP2019532919A (ja) | 2019-11-14 |
| US11459309B2 (en) | 2022-10-04 |
| CA3036064A1 (en) | 2018-03-15 |
| EP3510023A1 (en) | 2019-07-17 |
| US20190202805A1 (en) | 2019-07-04 |
| KR20190052040A (ko) | 2019-05-15 |
| US20200361901A1 (en) | 2020-11-19 |
| US10774069B2 (en) | 2020-09-15 |
| BR112019004517A2 (pt) | 2019-08-13 |
| KR102587178B1 (ko) | 2023-10-06 |
| MX2019002615A (es) | 2019-10-15 |
| EP3510023B1 (en) | 2024-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX390964B (es) | Formas cristalinas de un inhibidor tipo lisil oxidasa 2 y metodos de realizacion. | |
| PH12020551578A1 (en) | Modulators of methyl modifying enzymes, compositions and uses thereof | |
| MX376835B (es) | Inhibidores de lisil oxidasa tipo 2 fluorinados y usos de los mismos. | |
| JOP20200001A1 (ar) | كاربوكسأميدات بوصفها معدلات لقنوات الصوديوم | |
| EA200901486A1 (ru) | СОЕДИНЕНИЯ И КОМПОЗИЦИИ, КАК ИНГИБИТОРЫ КИНАЗЫ c-KIT И PDGFR | |
| PH12013502316A1 (en) | Halogen-alkyl-1,3 oxazines as bace1 and/or bace2 inhibitors | |
| WO2017210545A8 (en) | Potassium channel modulators | |
| MX377837B (es) | Compuestos de indol carboxamida utiles como inhibidores de cinasas. | |
| EA200970447A1 (ru) | Соединения и композиции в качестве ингибиторов протеинкиназы | |
| HK1199725A1 (en) | Heterocyclic compounds and uses thereof | |
| HK1198443A1 (en) | Heterocyclic compounds and uses thereof | |
| NI201200072A (es) | Métodos y composiciones para tratar cáncer | |
| MX377802B (es) | Metodos y composiciones para trastornos del sueño y otros trastornos. | |
| DK2026803T3 (da) | Sammensætninger af R(+) og S(-) pramipexol og fremgangsmåder til anvendelse heraf | |
| NO20091989L (no) | Forbindelser som modulerer c-fms og/eller C-kit aktivitet og deres anvendelse | |
| MX2019000536A (es) | Nuevas pirimidinas carboxamidas como inhibidores de enzima vanina-1. | |
| MX2009007944A (es) | Compuestos y composiciones de purina como inhibidores de quinasa para el tratamiento de enfermedades relacionadas con plasmodium. | |
| AR068768A1 (es) | Derivados de tetrahidroquinolina para tratar trastornos por estres post - traumatico | |
| CR20150050A (es) | Sales y formas solidas de (s)-3-(4-((4-(morfolinometil) bencil) oxi)-1-oxoisoindolin-2-il) piperidin-2, 6-diona y composiciones que comprenden y métodos para utilizar las mismas | |
| MX2013007957A (es) | 1,4-oxazinas como inhibidores de los genes de enzima de segmentacion de la proteina precursora amiloide del sitio beta 1 y/o (bace1 y/o bace2). | |
| MX2019002439A (es) | Derivados de n-(piridin-2-il) piridina-sulfonamida y su uso en el tratamiento de enfermedades. | |
| TW201713650A (en) | NADPH oxidase 4 inhibitors | |
| BR112015002183A2 (pt) | processos para a preparação de (s) -3- (4 - ((4- (morfolinometil) benzil) oxi) -1-oxoisoindolin-2-il) -piperidina-2,6-diona e formas farmaceuticamente aceitáveis da mesma | |
| HK1251566A1 (zh) | 作为hdac1/2抑制剂的呱啶衍生物 | |
| BRPI0820668A2 (pt) | Derivados de oxindol substituídos por 5-halogênio e seu uso para tratar doenças dependentes de vasopressina |